Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Prevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited.In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, patients were treated wit...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4231065?pdf=render |
id |
doaj-804f77fa801a49138c380ea6cd75f0ba |
---|---|
record_format |
Article |
spelling |
doaj-804f77fa801a49138c380ea6cd75f0ba2020-11-25T02:47:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01911e11265810.1371/journal.pone.0112658Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.Elena G KamburovaHans J P M KoenenMartijn W F van den HoogenMarije C BaasIrma JoostenLuuk B HilbrandsPrevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited.In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, patients were treated with tacrolimus, mycophenolate mofetil (MMF), steroids, and a single dose of rituximab or placebo during transplant surgery. In a subset of patients, we analyzed the number and phenotype of peripheral T and B cells by multiparameter flow cytometry before transplantation, and at 3, 6, 12, and 24 months after transplantation.In patients treated with tacrolimus/MMF/steroids the proportion of central memory CD4+ and CD8+ T cells was higher at 3 months post-transplant compared to pre-transplant levels. In addition, the ratio between the percentage of central memory CD4+ and CD4+ regulatory T cells was significantly higher up to 24 months post-transplant compared to pre-transplant levels. Interestingly, treatment with tacrolimus/MMF/steroids resulted in a shift toward a more memory-like B-cell phenotype post-transplant. Addition of a single dose of rituximab resulted in a long-lasting B-cell depletion. At 12 months post-transplant, the small fraction of repopulated B cells consisted of a high percentage of transitional B cells. Rituximab treatment had no effect on the T-cell phenotype and function post-transplant.Renal transplant recipients treated with tacrolimus/MMF/steroids show an altered memory T and B-cell compartment post-transplant. Additional B-cell depletion by rituximab leads to a relative increase of transitional and memory-like B cells, without affecting T-cell phenotype and function.ClinicalTrials.gov NCT00565331.http://europepmc.org/articles/PMC4231065?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena G Kamburova Hans J P M Koenen Martijn W F van den Hoogen Marije C Baas Irma Joosten Luuk B Hilbrands |
spellingShingle |
Elena G Kamburova Hans J P M Koenen Martijn W F van den Hoogen Marije C Baas Irma Joosten Luuk B Hilbrands Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. PLoS ONE |
author_facet |
Elena G Kamburova Hans J P M Koenen Martijn W F van den Hoogen Marije C Baas Irma Joosten Luuk B Hilbrands |
author_sort |
Elena G Kamburova |
title |
Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. |
title_short |
Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. |
title_full |
Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. |
title_fullStr |
Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. |
title_full_unstemmed |
Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. |
title_sort |
longitudinal analysis of t and b cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Prevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on their in vivo effects on T- and B-cell phenotype and function are limited.In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, patients were treated with tacrolimus, mycophenolate mofetil (MMF), steroids, and a single dose of rituximab or placebo during transplant surgery. In a subset of patients, we analyzed the number and phenotype of peripheral T and B cells by multiparameter flow cytometry before transplantation, and at 3, 6, 12, and 24 months after transplantation.In patients treated with tacrolimus/MMF/steroids the proportion of central memory CD4+ and CD8+ T cells was higher at 3 months post-transplant compared to pre-transplant levels. In addition, the ratio between the percentage of central memory CD4+ and CD4+ regulatory T cells was significantly higher up to 24 months post-transplant compared to pre-transplant levels. Interestingly, treatment with tacrolimus/MMF/steroids resulted in a shift toward a more memory-like B-cell phenotype post-transplant. Addition of a single dose of rituximab resulted in a long-lasting B-cell depletion. At 12 months post-transplant, the small fraction of repopulated B cells consisted of a high percentage of transitional B cells. Rituximab treatment had no effect on the T-cell phenotype and function post-transplant.Renal transplant recipients treated with tacrolimus/MMF/steroids show an altered memory T and B-cell compartment post-transplant. Additional B-cell depletion by rituximab leads to a relative increase of transitional and memory-like B cells, without affecting T-cell phenotype and function.ClinicalTrials.gov NCT00565331. |
url |
http://europepmc.org/articles/PMC4231065?pdf=render |
work_keys_str_mv |
AT elenagkamburova longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy AT hansjpmkoenen longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy AT martijnwfvandenhoogen longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy AT marijecbaas longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy AT irmajoosten longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy AT luukbhilbrands longitudinalanalysisoftandbcellphenotypeandfunctioninrenaltransplantrecipientswithorwithoutrituximabinductiontherapy |
_version_ |
1724754904510103552 |